Partnering: VasoDynamics Signs a Partnership Agreement with Beijing Regitrans and a local pharmaceutical company to perform preIND meeting with China NMPA

30th -January- 2026

VasoDynamics Ltd, the pharmaceutical company developing patient-friendly, cost-effective therapies for the prevention/reduction of debilitating side-effects induced by anti-cancer treatments, is pleased to announce the signing of a partnership with Beijing Regitrans Co. Ltd., supported by a mid-size local pharmaceutical company, to perform the pre-IND meeting with China National Medicine Products Administration (NMPA) on its first-of-kind innovative medicine for the prevention/reduction of radiodermatitis in preparation for the registration trials and future market approval in China.

Dr Ningfeng Fiona Li, CEO of VasoDynamics, said:

“Regitrans has a team of experts with a wealth of hands-on working experience with the regulatory bodies in China. We are delighted to partner with Regitrans to perform the pre-IND meeting with China NMPA to map out the clinical development and market approval path in China for our radiodermatitis prevention product, so to obtain the clarity on China market access requirements, and further support our licensing discussions with local pharma company to move forward.”